Blood:造血细胞高表达CXCL4促进MPN骨髓纤维化进展

2020-08-05 MedSci原创 MedSci原创

细胞因子CXCL4/血小板因子4(PF4)的空间差异性表达标志着纤维化的进展;造血细胞CXCL4缺乏可减轻MPN表型,减少基质细胞激活和骨髓纤维化。

原发性骨髓纤维化(PMF)是一种骨髓增生性肿瘤(MPN),可导致骨髓(BM)进行性纤维化。虽然已广泛研究了参与PMF发病机制的细胞突变,但通过造血-基质交联的驱动基质激活和纤维化的顺序事件仍未明确。

通过非偏倚方法并在MPN患者中进行了验证,研究人员明确了趋化因子CXCL4/血小板因子4(PF4)的空间差异性表达标志着纤维化的进展。

造血细胞CXCL4缺乏可改善MPN表型,减少基质细胞活化和BM纤维化,并可减少3种PMF小鼠模型的:1)巨核细胞促纤维化通路的激活;2)纤维化驱动细胞炎症;3)巨核细胞和基质细胞的JAK/STAT激活。

该研究表明,在MPN中,CXCL4高表达具有促纤维化效应,是特征性炎症的调节因子。因此,靶向CXCL4或可成为一种减轻PMF炎症的有效方法。

原始出处:

Helene Gleitz,et al. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood. July 29,2020.

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1681876, encodeId=3f3c16818e6e6, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Fri Dec 04 22:51:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935500, encodeId=3824193550002, content=<a href='/topic/show?id=4302121e605' target=_blank style='color:#2F92EE;'>#MPN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12176, encryptionId=4302121e605, topicName=MPN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Nov 09 17:51:13 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494747, encodeId=82ed1494e4700, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Aug 07 08:51:13 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621141, encodeId=de56162114144, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Fri Aug 07 08:51:13 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806505, encodeId=ba3c806505ec, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:34:13 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2020-12-04 ailian1211

    #血细胞#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1681876, encodeId=3f3c16818e6e6, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Fri Dec 04 22:51:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935500, encodeId=3824193550002, content=<a href='/topic/show?id=4302121e605' target=_blank style='color:#2F92EE;'>#MPN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12176, encryptionId=4302121e605, topicName=MPN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Nov 09 17:51:13 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494747, encodeId=82ed1494e4700, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Aug 07 08:51:13 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621141, encodeId=de56162114144, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Fri Aug 07 08:51:13 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806505, encodeId=ba3c806505ec, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:34:13 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2020-11-09 12498568m50暂无昵称

    #MPN#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1681876, encodeId=3f3c16818e6e6, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Fri Dec 04 22:51:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935500, encodeId=3824193550002, content=<a href='/topic/show?id=4302121e605' target=_blank style='color:#2F92EE;'>#MPN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12176, encryptionId=4302121e605, topicName=MPN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Nov 09 17:51:13 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494747, encodeId=82ed1494e4700, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Aug 07 08:51:13 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621141, encodeId=de56162114144, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Fri Aug 07 08:51:13 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806505, encodeId=ba3c806505ec, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:34:13 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2020-08-07 俅侠

    #造血#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1681876, encodeId=3f3c16818e6e6, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Fri Dec 04 22:51:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935500, encodeId=3824193550002, content=<a href='/topic/show?id=4302121e605' target=_blank style='color:#2F92EE;'>#MPN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12176, encryptionId=4302121e605, topicName=MPN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Nov 09 17:51:13 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494747, encodeId=82ed1494e4700, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Aug 07 08:51:13 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621141, encodeId=de56162114144, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Fri Aug 07 08:51:13 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806505, encodeId=ba3c806505ec, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:34:13 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2020-08-07 lq1774
  5. [GetPortalCommentsPageByObjectIdResponse(id=1681876, encodeId=3f3c16818e6e6, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Fri Dec 04 22:51:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935500, encodeId=3824193550002, content=<a href='/topic/show?id=4302121e605' target=_blank style='color:#2F92EE;'>#MPN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12176, encryptionId=4302121e605, topicName=MPN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Nov 09 17:51:13 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494747, encodeId=82ed1494e4700, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Aug 07 08:51:13 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621141, encodeId=de56162114144, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Fri Aug 07 08:51:13 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806505, encodeId=ba3c806505ec, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:34:13 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2020-08-06 ms3000000449926787

    学习了

    0

相关资讯

2015原发性骨髓纤维化诊断与治疗中国专家共识发布

近年来原发性骨髓纤维化(PMF)的研究进展迅猛,为给我国血液科医生提供规范化的临床实践指导,由中华医学会血液学分会白血病淋巴瘤学组牵头组织国内相关专家,从循证医学角度出发,经广泛征求意见并反复多次修改,在PMF的诊断程序、实验室检查、诊断标准和治疗原则等方面最终达成共识。 一、名词和术语 按骨髓纤维化(MF)研究和治疗国际工作组(IWG-MRT)达成的术语共识,推荐使用PM

Blood:ECM-整合素受体轴在原发性骨髓纤维化巨核细胞异常增殖中的作用

整合素a5b1的a5亚基在PMF的JAK2V617F+巨核细胞中表达上调,导致对纤连蛋白的粘附性增强。 无论是在体内还是体外,抗体介导的a5亚基抑制均可阻止JAK2V617F+巨核细胞谱系扩增。